DTC
CBIO

Deep Track Capital’s Crescent Biopharma CBIO Stock Holding History

Deep Track Capital’s Portfolio CBIO Stock Details CBIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-453,686
Closed -$8.33M – 76
2026
Q1 		$8.33M Hold
453,686
– – 0.14% 58
2025
Q4 		$5.38M Hold
453,686
– – 0.1% 49
2025
Q3 		$5.39M Hold
453,686
– – 0.15% 48
2025
Q2 		$7.32M Buy
+453,686
New +$9.6M 0.23% 47

Other funds holding CBIO

FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.51B AUM 546.08% 1-Year Est. Return
LGM
Logos Global Management San Francisco, California $2.32B AUM 536.01% 1-Year Est. Return
FIS
FCPM III Services Naarden, Netherlands $750M AUM 127.27% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $80.2B AUM 51.53% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
BCM
Boxer Capital Management San Diego, California $1.33B AUM 864.5% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return
NCM
NEXTBio Capital Management Menlo Park, California $217M AUM

Deep Track Capital's CBIO Position: Q2 2026 in Review

Deep Track Capital sold out of Crescent Biopharma (CBIO) in Q2 2026, closing a stake of 453,686 shares — an estimated $8.33M sold.

Deep Track Capital first reported a position in CBIO in Q2 2025 and held it in 4 quarters. The position peaked at $8.33M in Q1 2026. 70 funds tracked by Wall St. Rank hold CBIO as of Q2 2026.

  • Deep Track Capital reported no remaining Crescent Biopharma position as of Q2 2026 after selling out during the quarter.
  • Deep Track Capital sold 453,686 Crescent Biopharma shares in Q2 2026, an estimated $8.33M.
  • Deep Track Capital first reported a position in Crescent Biopharma in Q2 2025 and held it in 4 quarters.
  • Deep Track Capital's Crescent Biopharma position peaked at $8.33M in Q1 2026.
  • 70 funds tracked by Wall St. Rank held Crescent Biopharma as of Q2 2026.

Based on Deep Track Capital's 13F filing for Q2 2026, filed 14 Aug 2026.